C-(3,4-Dihydro-naphthalen-2-yl)-methylamine | 3262-09-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: C-(3,4-Dihydro-naphthalen-2-yl)-methylamine
• 英文别名: 3,4-Dihydronaphthalen-2-ylmethanamine
• CAS: 3262-09-7
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: FLLJGSGKUKOKKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Novel compounds
  申请人：SmithKline Beecham SpA

  公开号：US20040024218A1

  公开（公告）日：2004-02-05

  Compounds of formula I, or a salt thereof or a hydrate thereof, as follows: 1 wherein X and Y are selected independently from hydrogen and aryl, which aryl is unsubstituted or substituted one or more times by hydroxy, hydroxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, aryl, heterocyclyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkoxy or halo, which alkyl or alkoxy groups are unsubstituted or substituted one or more times by halo; m and n are independently 0 to 3, provided that m and n are not both 0; A represents a single bond or is —(CR pa R pb ) p — wherein p is 1-3 and R pa and R pb are selected independently from hydrogen, C 1-6 alkyl, C 1-6 alkoxy and halo, which alkyl or alkoxy groups are independently substituted one or more times by halo; B represents a C 4-8 saturated or unsaturated ring, which ring is unsubstituted or substituted one or more times by C 1-6 alkyl, C 1-6 alkoxy, aryl, aryloxy, hydroxy, oxo, halo, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C 1-6 alkylamido, which C 1-6 alkyl or C 1-6 alkoxy groups are unsubstituted or substituted one or more times by halo, which aryl group is unsubstituted or substituted one or more times by aryl, heterocyclyl, aryloxy, arylC 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkyl, hydroxy, C 1-6 alkenoxy, C 1-6 alkoxy, halo, or C 1-6 alkyl, which C 1-6 alkyl may be substituted one or more times by halo, and which aryl group is linked to said ring by a single bond or is benzo-condensed therewith are ligands of the ORL-1 receptor.

  式I的化合物，或其盐或水合物，如下所示：其中X和Y分别选择自氢和芳基，所述芳基未取代或被羟基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、芳基、杂环烷基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷氧基、C1-6烷基、C1-6烷氧基或卤素取代一次或多次，其中烷基或烷氧基基团未取代或被卤素取代一次或多次；m和n独立地为0到3，但要求m和n不能同时为0；A代表单键或为—(CRpaRpb)p—，其中p为1-3且Rpa和Rpb独立选择自氢、C1-6烷基、C1-6烷氧基和卤素，其中烷基或烷氧基基团独立地被卤素取代一次或多次；B代表C4-8饱和或不饱和环，所述环未取代或被C1-6烷基、C1-6烷氧基、芳基、芳氧基、羟基、氧代、卤素、氨基、C1-6烷基氨基、二(C1-6烷基)氨基和C1-6烷酰胺取代一次或多次，其中C1-6烷基或C1-6烷氧基基团未取代或被卤素取代一次或多次，所述芳基未取代或被芳基、杂环烷基、芳氧基、芳基C1-6烷氧基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷基、羟基、C1-6烯氧基、C1-6烷氧基、卤素或C1-6烷基取代一次或多次，所述C1-6烷基可能被卤素取代一次或多次，所述芳基通过单键与所述环相连或与之苯并结合的化合物是ORL-1受体的配体。
• [EN] BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS<br/>[FR] COMPOSES DE BENZOSUBERONYLPIPERIDINE COMME ANALGESIQUES
  申请人：SMITHKLINE BEECHAM SPA

  公开号：WO2001083454A1

  公开（公告）日：2001-11-08

  Compounds of formula (I) or a derivative thereof, wherein; R is C1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, hydroxy, halo, C1-6alkenyl, C1-6alkynyl, amino, C1-6alkylamino, di(C1-6alkyl)amino, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl; R1 is hydrogen or R; R2 is hydroxy, C¿1-6?alkoxy, amino, C1-6alkylamino, di(C1-6alkyl)amino; R?3¿ is hydrogen or C¿1-6?alkyl; R?4 and R5¿ are each independently selected from the list consisting of perhaloC¿1-6?alkyl, hydrogen, halo, C1-6alkyl, C1-6alkoxy, hydroxy, amino, C1-6alkylamino, di(C1-6alkyl)amino, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl, and COX wherein X may be hydroxy, C1-6alkoxy, C1-6alkyl, amino, C1-6alkylamino, or di(C1-6alkyl)amino; with the proviso that, when R?3¿ is hydrogen, then R?4 and R5¿ are not both hydrogen; and wherein any alkyl group or the alkyl moiety of any group containing such a moiety may be substituted one or more times by halo; are ligands of the ORL-1 receptor and are useful in therapy.

  式(I)或其衍生物的化合物，其中：R为C1-6烷基，C3-7环烷基，C1-6烷氧基，羟基，卤素，C1-6烯基，C1-6炔基，氨基，C1-6烷基氨基，二（C1-6烷基）氨基，羟基C1-6烷基，C1-6烷氧基C1-6烷基，氨基C1-6烷基，（C1-6烷基）氨基C1-6烷基，二（C1-6烷基）氨基C1-6烷基；R1为氢或R；R2为羟基，C1-6烷氧基，氨基，C1-6烷基氨基，二（C1-6烷基）氨基；R3为氢或C1-6烷基；R4和R5各自独立地从以下列表中选择：全卤素C1-6烷基，氢，卤素，C1-6烷基，C1-6烷氧基，羟基，氨基，C1-6烷基氨基，二（C1-6烷基）氨基，羟基C1-6烷基，C1-6烷氧基C1-6烷基，氨基C1-6烷基，（C1-6烷基）氨基C1-6烷基，二（C1-6烷基）氨基C1-6烷基，芳基和COX，其中X可以是羟基，C1-6烷氧基，C1-6烷基，氨基，C1-6烷基氨基或二（C1-6烷基）氨基；但是，当R3为氢时，R4和R5不同时为氢；其中任何烷基或含有此类基团的任何基团的烷基部分均可被卤素取代一次或多次；是ORL-1受体的配体，并且在治疗中有用。
• Benzosuberonylpiperdine compounds as analgesics
  申请人：——

  公开号：US20040029917A1

  公开（公告）日：2004-02-12

  Compounds of formula (I) or a derivative thereof, wherein; R is C 1-6 allkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, hydroxy, halo, C 1-6 alkenyl, C 1-6 allkynyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, hydroxyC 1-6 alkyl, C 1-6 akoxyC 1-6 alkyl, aminoC 1-6 allkyl, (C 1-6 allkyl)aminoC 1-6 alkyl, di(C 1-6 allkyl)aminoC 1-6 alkyl; R 1 is hydrogen or R; R 2 is hydroxy, C 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino; R 3 is hydrogen or C 1-6 alkyl; R 4 and R 5 are each independently selected from the list consisting of perhaloC 1-6 alkyl, hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, amino, C 1-6 akylamino, di(C 1-4 alkyl)amino, hydroxyC 1-6 alkyl, C 1-6 akoxyC 1-6 alkyl, aminoC 1-6 allkyl, (C 1-4 alkyl)aminoC 1-6 alkyl, di(C 1-4 alkyl)aminoC 1-4 alkyl, aryl, and COX wherein X may be hydroxy, C 1-6 alkoxy, C 1-6 alkyl, amino, C 1-6 alkylamino, or di(C 1-6 allkyl)amino; with the proviso that, when R 3 is hydrogen, then R R 4 and R 5 are not both hydrogen; and wherein any alkyl group or the alkyl moiety of any group containing such a moiety may be substituted one or more times by halo; are ligands of the ORL-1 receptor and are useful in therapy. 1

  式(I)或其衍生物的化合物，其中：R是C1-6烷基，C3-7环烷基，C1-6烷氧基，羟基，卤素，C1-6烯基，C1-6炔基，氨基，C1-6烷基氨基，二（C1-6烷基）氨基，羟基C1-6烷基，C1-6烷氧基C1-6烷基，氨基C1-6烷基，（C1-6烷基）氨基C1-6烷基，二（C1-6烷基）氨基C1-6烷基；R1是氢或R；R2是羟基，C1-6烷氧基，氨基，C1-6烷基氨基，二（C1-6烷基）氨基；R3是氢或C1-6烷基；R4和R5各自独立地选自以下列表中的物种：全卤素C1-6烷基，氢，卤素，C1-6烷基，C1-6烷氧基，羟基，氨基，C1-6烷基氨基，二（C1-4烷基）氨基，羟基C1-6烷基，C1-6烷氧基C1-6烷基，氨基C1-6烷基，（C1-4烷基）氨基C1-6烷基，二（C1-4烷基）氨基C1-4烷基，芳基，和COX，其中X可以是羟基，C1-6烷氧基，C1-6烷基，氨基，C1-6烷基氨基或二（C1-6烷基）氨基；但是，当R3是氢时，R、R4和R5不能同时为氢；其中任何烷基或含有此类基团的任何基团的烷基部分可以被卤素取代一次或多次；是ORL-1受体的配体，并且在治疗中有用。
• Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases
  申请人：Salter-Cid M. Luisa

  公开号：US20070078157A1

  公开（公告）日：2007-04-05

  Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.

  本发明公开了抑制半卡巴肼敏感性胺氧化酶（SSAO），也称为血管黏附蛋白-1（VAP-1）的组合物和方法。所公开的化合物是含有胺基和酰胺基的化合物。这些化合物和组合物可用于治疗炎症、炎症性疾病和自身免疫性疾病等疾病。
• AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES
  申请人：SALTER-CID LUISA M.

  公开号：US20120172392A1

  公开（公告）日：2012-07-05

  Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.

  本文揭示了一种抑制半卡巴肼敏感性胺氧化酶（SSAO），也称为血管粘附蛋白-1（VAP-1）的组合物和方法。所揭示的化合物包括含胺和含酰胺的化合物。这些化合物和组合物对于治疗疾病，包括炎症、炎症性疾病和自身免疫性疾病非常有用。